ARTICLE | Product Development
The radiotherapy is one of multiple modalities J&J is testing against KLK2, which could enable tumor-specific targeting across prostate cancer stages
By Karen Tkach Tuzman, Director of Biopharma Intelligence
May 24, 2024 11:48 PM UTC


As the radiopharmaceutical field shifts its focus to high-potency α particle-emitters, Phase I data from J&J is probing both the promise and the dosing limits of actinium-225, the most widely pursued radioisotope in the class.
The pharma believes the data help validate its target thesis. It is one of few companies pursuing KLK2 for prostate cancer, and the only one with a disclosed radiopharmaceutical against the protein in a field awash with PSMA-targeting agents…
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/652515/j-j-data-at-asco-probe-new-target-space-toxicity-limits-for-actinium